

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 September 2022 (22.09.2022)



(10) International Publication Number
WO 2022/198040 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) C07K 16/30 (2006.01)

(21) International Application Number:
PCT/US2022/020937

(22) International Filing Date:
18 March 2022 (18.03.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/163,680 19 March 2021 (19.03.2021) US

(71) Applicant: **ELPIS BIOPHARMACEUTICALS**
[US/US]; 128 Spring Street, Lexington, Massachusetts
02421 (US).

(72) Inventors: **ZHAO, Kehao**; c/o Elpis Biopharmaceuti-
cals, 128 Spring Street, Lexington, Massachusetts 02421
(US). **CHEN, Yan**; c/o Elpis Biopharmaceuti-
cals, 128 Spring Street, Lexington, Massachusetts 02421 (US).
HASSAN, Samuel Clement; c/o Elpis Biopharmaceuti-
cals, 128 Spring Street, Lexington, Massachusetts 02421
(US). **NGUYEN, Jenna**; c/o Elpis Biopharmaceuti-
cals, 128 Spring Street, Lexington, Massachusetts 02421 (US).

JIANG, Ning; c/o Elpis Biopharmaceuticals, 128 Spring
Street, Lexington, Massachusetts 02421 (US).


(74) Agent: **CHEN, Yahua** et al.; The McDermott Building, 500
North Capitol Street, N.W., Washington, District of Colum-
bia 20001 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: ANTIBODIES SPECIFIC TO SIALIC ACID-BINDING IG-LIKE LECTIN 15 AND USES THEREOF

FIG. 1



(57) Abstract: Disclosed herein are high affinity anti-Siglec15 antibodies and methods of using such for therapeutic and/or diagnostic purposes. Also provided herein are methods for producing such anti-Siglec15 antibodies.

[Continued on next page]

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*
- *with sequence listing part of description (Rule 5.2(a))*